This report provides a comprehensive analysis of the Europe pain management drugs market, which is projected to experience significant growth through 2033. The study examines various drug categories, including NSAIDs and opioids, while highlighting key drivers such as the rapid development of novel pharmacological treatments. Although the market faces challenges from rising interest in non-pharmacological alternatives and strict opioid regulations, continuous innovation in drug formulations remains a central industry trend.

Executive Overview

The Europe pain management drugs market reached US$ 17.13 billion in 2024 and is projected to reach US$ 33.77 billion by 2033, growing at a CAGR of 7.9% during the forecast period of 2025-2033.

Pain management drugs, also referred to as analgesics, are medications designed to alleviate pain. These medications are classified into several categories, primarily including:

• Non-steroidal anti-inflammatory drugs (NSAIDs)
• Opioids
• Corticosteroids
• Muscle relaxants
• Anticonvulsants

Drug Functionality & Classifications:

• NSAIDs: Commonly utilized for mild to moderate pain and effective in reducing inflammation.
• Opioid Analgesics: Stronger medications (e.g., morphine and oxycodone) prescribed for moderate to severe pain; they function by binding to specific receptors in the brain to block pain perception.
• Nerve & Chronic Pain Management: Anticonvulsants, antidepressants, and adjuvant analgesics are effective for managing nerve pain and chronic pain syndromes.

Market Dynamics

Drivers

Rising Development of Novel Drugs: A primary driver for market growth is the increasing development of novel drugs. As research and technology advance, pharmaceutical companies are focusing on creating new, more effective treatments for pain.

• Example (Haleon): In February 2025, Haleon launched the 24-hour Voltarol Medicated Plaster in the UK. This topical drug contains diclofenac sodium (an anti-inflammatory ingredient) and is designed to provide continuous relief for up to 24 hours for muscle and joint pain resulting from strains, sprains, and sports injuries.
• Example (Algiax Pharmaceuticals): In February 2025, Algiax Pharmaceuticals announced positive topline data from its Phase 2a clinical trial of AP-325, an innovative treatment for chronic neuropathic pain. AP-325 acts as an allosteric GABAA-receptor modulator and demonstrated the ability to rapidly reduce neuropathic pain with long-term benefits. The trial was conducted across Germany, Spain, the Czech Republic, Belgium, and France, involving 99 participants to evaluate AP-325 as a monotherapy for peripheral post-surgical neuropathic pain.

Restraints

Competition from Alternative Pain Management Treatments: The growth of the market is challenged by the shift toward non-pharmacological options as patients seek drug-free treatments due to rising health awareness. This competition is expected to limit the demand for traditional drugs, necessitating innovation from pharmaceutical companies.

• Non-Pharmacological Approaches Gaining Traction: Acupuncture, hypnosis, massage, mindfulness meditation, music-based interventions, spinal manipulation, tai chi, qigong, and yoga.
• Other Emerging Alternative Therapies: Chiropractic therapies, therapeutic touch, certain herbal therapies, and dietary approaches.

Segment Analysis

The Europe pain management drugs market is segmented by drug type, indication, mode of prescription, and distribution channel.

Drug Type: Opioids

Opioids are expected to dominate the market with the highest market share. They remain the most effective treatment for severe pain, including cancer-related, post-surgical, and neuropathic pain.

• Common Medications: Oxycodone, hydrocodone, codeine, morphine, and fentanyl.
• Market Challenges: Despite their efficacy, opioid addiction is a significant public health challenge, leading to increased scrutiny and stricter regulatory controls in Europe.
• Industry Response: Pharmaceutical companies are focusing on abuse-deterrent formulations (ADF) and non-opioid treatments. Key players such as Purdue Pharma, Teva Pharmaceuticals, and Mallinckrodt Pharmaceuticals are active in this space, while Pfizer and Collegium Pharmaceutical are advancing extended-release formulations to enhance control while minimizing abuse potential.
• Usage Drivers:
• Surgical Pain: 40-50% of post-operative patients require opioids for pain relief.
• Trauma: Severe trauma pain contributes substantially to usage.
• Chronic Pain: Chronic diffuse pain affects 10% to 15% of the global adult population.
• Palliative Care: End-of-life care remains a crucial sector for opioid-based relief.

Competitive Landscape

Major Players in Europe

• Bayer AG
• Haleon
• Grünenthal GmbH
• ZAMBON COMPANY S.P.A.
• Viatris Inc
• Pfizer Plc
• Kenvue Brands LLC
• Adalvo
• Mundipharma Ges.m.b.H.
• Evotec SE

Key Developments

• Saridon (August 2024): The leading Indian pain relief brand launched 'Saridon Woman,' a unique solution for period pain targeting abdominal cramps, backaches, and headaches, supported by the #NoPainPeriod campaign.

Report Information

Why Purchase This Report?

• Technological Innovations: Reviews clinical trials, product pipelines, and upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes performance and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into development.
• Physician Preferences & Health System Impact: Examines provider behaviors and the impact of health system mergers.
• Market Updates & Industry Changes: Covers regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and access strategies.
• Market Entry & Expansion: Identifies strategies for entering new markets and forming partnerships.
• Supply Chain Optimization: Assesses risks and distribution strategies.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving healthcare regulations.
• Post-market Surveillance: Uses post-market data to enhance product safety.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift toward value-based pricing and data-driven R&D.

Report Specifications

• Total Pages: 159
• Key Tables: 42
• Visual Figures: More than 43

Target Audience

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Application & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

• 1 Market Introduction and Scope

  • 1.1 Objectives of the Report

  • 1.2 Report Coverage & Definitions

  • 1.3 Report Scope

• 2 Executive Insights and Key Takeaways

  • 2.1 Market Highlights and Strategic Takeaways

  • 2.2 Key Trends and Future Projections

  • 2.3 Snippet by Drug Type

  • 2.4 Snippet by Indication

  • 2.5 Snippet by Mode of Prescription

  • 2.6 Snippet by Distribution Channel

• 3 Dynamics

  • 3.1 Impacting Factors

    • 3.1.1 Drivers

      • 3.1.1.1 Rising Development of Novel Drugs
      • 3.1.1.2 Rising Prevalence of Chronic Pain Conditions
      • 3.1.1.3 XX

    • 3.1.2 Restraints

      • 3.1.2.1 Competition from Alternative Pain Management Treatments
      • 3.1.2.2 Side Effects Associated with the Drugs
      • 3.1.2.3 XX

    • 3.1.3 Opportunity

      • 3.1.3.1 Market Expansion for Pain Management Drugs in Low-income Countries
      • 3.1.3.2 XX

    • 3.1.4 Impact Analysis

• 4 Strategic Insights and Industry Outlook

  • 4.1 Market Leaders and Pioneers

    • 4.1.1 Emerging Pioneers and Prominent Players

    • 4.1.2 Established leaders with largest selling Brand

    • 4.1.3 Market leaders with established Product

  • 4.2 CXO Perspectives

  • 4.3 Latest Developments and Breakthroughs

  • 4.4 Case Studies/Ongoing Research

  • 4.5 Regulatory and Reimbursement Landscape

  • 4.6 Porter’s Five Force Analysis

  • 4.7 Supply Chain Analysis

  • 4.8 SWOT Analysis

  • 4.9 Unmet Needs and Gaps

  • 4.10 Recommended Strategies for Market Entry and Expansion

  • 4.11 Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts

  • 4.12 Pricing Analysis and Price Dynamics

  • 4.13 Key Opinion Leaders

• 5 By Drug Type

  • 5.1 Introduction

    • 5.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

    • 5.1.2 Market Attractiveness Index, By Drug Type

  • 5.2 Non-Steroidal Anti-Inflammatory Drugs*

    • 5.2.1 Introduction

    • 5.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)

  • 5.3 Opioids

  • 5.4 Corticosteroids

  • 5.5 Muscle Relaxants

  • 5.6 Anticonvulsant Drugs

  • 5.7 Others

• 6 By Indication

  • 6.1 Introduction

    • 6.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

    • 6.1.2 Market Attractiveness Index, By Indication

  • 6.2 Arthritis Pain*

    • 6.2.1 Introduction

    • 6.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)

  • 6.3 Back Pain

  • 6.4 Surgery Pain

  • 6.5 Headaches & Migraine

  • 6.6 Injury Pain

  • 6.7 Cancer Pain

  • 6.8 Fibromyalgia

  • 6.9 Muscle Spasms

  • 6.10 Menstrual Pain

  • 6.11 Neuropathic Pain

  • 6.12 Others

• 7 By Mode of Prescription

  • 7.1 Introduction

    • 7.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Prescription

    • 7.1.2 Market Attractiveness Index, By Mode of Prescription

  • 7.2 Prescription Based*

    • 7.2.1 Introduction

    • 7.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)

  • 7.3 Over-the-Counter

• 8 By Distribution Channel

  • 8.1 Introduction

    • 8.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

    • 8.1.2 Market Attractiveness Index, By Distribution Channel

  • 8.2 Retail Pharmacies*

    • 8.2.1 Introduction

    • 8.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)

  • 8.3 Hospital Pharmacies

  • 8.4 Clinics

  • 8.5 Online Pharmacies

  • 8.6 Others

• 9 Competitive Landscape and Market Positioning

  • 9.1 Competitive Overview and Key Market Players

  • 9.2 Market Share Analysis and Positioning Matrix

  • 9.3 Strategic Partnerships, Mergers & Acquisitions

  • 9.4 Key Developments in Product Portfolios and Innovations

  • 9.5 Company Benchmarking

• 10 Company Profiles

  • 10.1 Bayer AG*

    • 10.1.1 Company Overview

    • 10.1.2 Product Portfolio

      • 10.1.2.1 Product Description
      • 10.1.2.2 Product Key Performance Indicators (KPIs)
      • 10.1.2.3 Historic and Forecasted Product Sales
      • 10.1.2.4 Product Sales Volume

    • 10.1.3 Financial Overview

      • 10.1.3.1 Company Revenue’s
      • 10.1.3.2 Geographical Revenue Shares
      • 10.1.3.3 Revenue Forecasts

    • 10.1.4 Key Developments

      • 10.1.4.1 Mergers & Acquisitions
      • 10.1.4.2 Key Product Development Activities
      • 10.1.4.3 Regulatory Approvals, etc

    • 10.1.5 SWOT Analysis

  • 10.2 Haleon

  • 10.3 Grünenthal GmbH

  • 10.4 ZAMBON COMPANY S.P.A

  • 10.5 Viatris Inc

  • 10.6 Pfizer Plc

  • 10.7 Kenvue Brands LLC

  • 10.8 Adalvo

  • 10.9 Mundipharma Ges.m.b.H

  • 10.10 Evotec SE

• 11 Assumption and Research Methodology

  • 11.1 Data Collection Methods

  • 11.2 Data Triangulation

  • 11.3 Forecasting Techniques

  • 11.4 Data Verification and Validation

• 12 Appendix

  • 12.1 About Us and Services

  • 12.2 Contact Us